| Market Capitalization (Millions $) |
180 |
| Shares
Outstanding (Millions) |
85 |
| Employees |
83 |
| Revenues (TTM) (Millions $) |
15 |
| Net Income (TTM) (Millions $) |
-54 |
| Cash Flow (TTM) (Millions $) |
32 |
| Capital Exp. (TTM) (Millions $) |
1 |
Ac Immune Sa
AC Immune SA is a Swiss clinical-stage biopharmaceutical company specializing in the development of small molecule and biological therapeutics for neurodegenerative diseases. Founded in 2003, the company has become a leading player in the field of Alzheimer's disease and related disorders.
AC Immune's drug discovery platform is based on proprietary technology for identifying and developing small molecules and biological molecules that target misfolded proteins implicated in neurodegenerative diseases. The company has developed a suite of proprietary assays for identifying these molecules and has a deep understanding of the structural biology and pathology of these diseases.
AC Immune's lead drug candidate is crenezumab, a humanized monoclonal antibody that targets beta-amyloid, a protein that accumulates in the brains of Alzheimer's patients. The company is also developing tau-targeting antibodies, including semorinemab and ACI-3024, for the treatment of Alzheimer's and other tauopathies.
In addition to drug development, AC Immune has a strong pipeline of diagnostic products for the early detection and monitoring of neurodegenerative diseases. These include tests for beta-amyloid and tau biomarkers, as well as a blood test for Alzheimer's disease.
AC Immune has partnerships with several major pharmaceutical companies, including Genentech, Eli Lilly, and Janssen Pharmaceuticals. The company is headquartered in Lausanne, Switzerland, with additional offices in the United States and Canada.
Overall, AC Immune is a leading biopharmaceutical company in the field of neurodegenerative diseases, with a robust drug discovery platform and a strong focus on developing treatments for Alzheimer's disease and related disorders. The company's innovative approach to drug development and diagnostics offers hope for patients suffering from these devastating diseases.
Company Address: EPFL INNOVATION PARK Lausanne 1015
Company Phone Number: 21 345 91 21 Stock Exchange / Ticker: NASDAQ ACIU
|
3.85%